Clentiazem

Drug Profile

Clentiazem

Alternative Names: Clentiazem maleate; Logna®; TA 3090

Latest Information Update: 16 Oct 2001

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Class Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies
  • Mechanism of Action Calcium channel antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Angina pectoris; Atherosclerosis; Hypertension; Reperfusion injury; Stroke; Supraventricular tachycardia; Transplant rejection

Most Recent Events

  • 16 Oct 2001 No-Development-Reported for Supraventricular tachycardia in Japan (IV)
  • 16 Oct 2001 No-Development-Reported for Reperfusion injury in Japan (Unknown route)
  • 16 Oct 2001 No-Development-Reported for Transplant rejection in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top